Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 191

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 191
---
 from certain lenders (out of which, an amount of $100,000 was received subsequent to December 31, 2024),
including Dr. Ehud Geller, the chairman and a member of our board of directors, and Pini Ben Elazar, a director nominee. The Bridge
Loans shall bear interest at 8% per annum until maturity and we agreed to pay the lenders an additional risk premium equal to 30% of
their respective loan amount. In October 2024, we amended the Bridge Loans pursuant to which the Bridge Loans may be extended beyond
March 31, 2025 and until June 30, 2025, subject to the Registration Statement effectiveness not later than March 31, 2025 and the
fulfillment of additional cumulative conditions. During September 2025, the Bridge Loans have been extended until November 30, 2025.
Furthermore, upon the occurrence of an initial public offering of our securities for a total offering of not less than $6,000,000 (a
“Qualified IPO”), the Bridge Loan lenders, shall be granted warrants to purchase such number of Ordinary Shares equal to
two times their respective loan amount in addition to the risk premium based on a price per share equal to 75% of the lowest price
per share of the Company’ Ordinary Shares during the first five trading days following the consummation of such initial public
offering. On July 1, 2025, we entered into an amendment to the Bridge Loan such that the Bridge Loan lenders shall be granted
warrants to purchase up to 140,000 Ordinary Shares following the consummation of this offering.

Between December 2023
and January 2024, we entered into loan agreements, or the 2024 Loan Agreements pursuant to which we obtained a loan in the aggregate
amount of $150,000 from certain lenders, including Dr. Ehud Geller, the chairman and a member of our board of directors and SCP Vitalife
Partners (which is affiliated with our director, Jeff Dykan). In October 2024, we amended the 2024 Loan Agreements pursuant to which
the 2024 Loan Agreements have been extended until August 31, 2025, shall bear interest at 8% per annum until maturity commencing as of
September 1, 2024, and we agreed to pay the lenders at maturity an additional aggregate amount of $50,000 as a risk premium. Furthermore,
upon